Home Search
geovax - search results
If you're not happy with the results, please do another search
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial!
Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants
We were having cocktails at...
GeoVax Labs (GOVX) JP Morgan 2024 Healthcare Conference Transcript.
(Presentation text bolding for emphasis by Editors of the Biotech Stock Review, not the company.
Adding GeoVax (GOVX) $3.32 to Reverse Stock Split Watch List.
Okay, Here's Our First Name for the Reverse Stock Split, Watch List. We'll Venture to Have 10 Names Added to Watch List...
GeoVax (GOVX) Research Reports Archive
Research Report Archive
Reports from Robert LeBoyer at Noble Capital. Jeffrey Kraws and Karen Goldfarb at Crystal Research....
Adding Geovax (GOVX) to 2024 Biotech Watch List.
GEOVAX (GOVX) $0.32
We added this to the Watch List earlier in the...
GeoVax Labs (GOVX) Video Presentation.
GeoVax’s COVID-19 vaccine candidates, which can induce strong antibody and T cell responses against the variants of the SARS-CoV-2 virus, also offers...
GeoVax (GOVX) Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox.
ATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against...
Adding GeoVax (GOVX) $0.52 to Watch List.
Report Out Next Week. Head's Up.
Price and time-stamping our returning interest at $0.52.
We're...
Bridging the Immunity Gap: An In-Depth Conversation with GeoVax’s (GOVX) CEO, David Dodd
In an era of rapid scientific development, the pharmaceutical industry constantly evolves to meet new challenges and seize emerging opportunities. GeoVax, a...
Ardelyx (ARDX) Reports First Quarter 2024 Showing $204 Million in Cash!
When we added Ardelyx (ARDX) to the Watch List in November of 2022, the market cap near $80 million. Now it's...